Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
Titel:
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
Auteur:
Ishola, David Manno, Daniela Afolabi, Muhammed O Keshinro, Babajide Bockstal, Viki Rogers, Baimba Owusu-Kyei, Kwabena Serry-Bangura, Alimamy Swaray, Ibrahim Lowe, Brett Kowuor, Dickens Baiden, Frank Mooney, Thomas Smout, Elizabeth Köhn, Brian Otieno, Godfrey T Jusu, Morrison Foster, Julie Samai, Mohamed Deen, Gibrilla Fadlu Larson, Heidi Lees, Shelley Goldstein, Neil Gallagher, Katherine E Gaddah, Auguste Heerwegh, Dirk Callendret, Benoit Luhn, Kerstin Robinson, Cynthia Leyssen, Maarten Greenwood, Brian Douoguih, Macaya Leigh, Bailah Watson-Jones, Deborah